Resources
10 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Patients Treated With Buprenorphine in Emergency Departments More Likely To Continue After Discharge
Posted 4/11/2023 (updated 3/27/2024)
In this cohort study of 17,428 Medicaid-enrolled adults with an emergency department encounter for opioid use disorder, the buprenorphine treatment Opioid Hospital Quality Improvement Program (O-HQIP) pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
Posted 11/1/2022 (updated 3/27/2024)
The webinar held by NASTAD on October 26, 2022, 4:00-5:30pm featured a dynamic discussion on integrating harm reduction principles and practices, including naloxone distribution, safe disposal, and harm reduction supply access, within the community health care setting. Health centers across the country that offer these services as part of comprehensive care shared their experiences and the ways that service expansion can contribute to engagement and care access.
Posted 6/8/2023 (updated 3/27/2024)
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD) with a relatively low rate of triggering precipitated withdrawal in patients. Increased precipitated withdrawal rates have become a concern for practitioners in emergency departments when treating with buprenorphine with the prevalence of fentanyl in the drug supply.
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 8/24/2020 (updated 3/28/2024)
AgriSafe is a national non profit that offers occupational health and safety training for rural health professionals. Currently AgriSafe in partnership with Mississippi State University Extension and University of Mississippi Medical Center are offering Continuing Health Professional Education through four webinars listed below. One hour of continuing education is available for each webinar.
This continuing education opportunity is free to licensed health care providers in the state of Mississippi. For health care providers outside of Mississippi, the continuing education is available for $40 per CE hour.
Posted 11/21/2019 (updated 3/28/2024)
The New York State Department of Health (NYSDOH) convened a Technical Working Group on Resuscitation Training in Naloxone Programs to ensure that overdose programs in New York State (NYS) and elsewhere are afforded the best possible resuscitation protocol guidance tailored to suspected opioid overdoses in diverse settings.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 12/9/2020 (updated 4/3/2024)
Emergency Department initiated buprenorphine. This guide includes an overview, list of protocols, tools, and assessments for providers.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.